Introduction
Epilepsy, the tendency to have recurrent unprovoked seizures, is the most common serious neurological disorder. Its prevalence ranges from 0.5 to 1% of the population in developed countries, and is probably higher in developing countries. 1 This condition is, however, merely a symptom of a wide variety of neurological disorders, ranging from self-limiting and benign to devastating and fatal. Regardless of the aetiology, the tendency to suffer recurrent seizures exposes persons with epilepsy to a variety of physical, psychological and social morbidities. 2 Complete control of seizures can negate these consequences to a large extent. 3 The majority of patients diagnosed with epilepsy can expect to achieve good control of seizures with antiepileptic drug (AED) therapy, 4,5 but a substantial minority will continue to experience seizures in spite of a range of AEDs used in adequate doses either singly or in combination. 6 Some patients whose seizures prove difficult to treat could benefit from non-pharmacological strategies, especially epilepsy surgery, which still remains one of the most underutilised effective treatment modalities worldwide. 7, 8 Early identification of patients whose seizures are likely to be pharmacoresistant would permit them to be offered referral for epilepsy surgery at the most appropriate juncture. 9 
Methodology
This short review will attempt to summarise data from relevant studies of outcomes in newly diagnosed epilepsy in paediatric and adult populations. These were identified from Pubmed using the search terms 'newly diagnosed epilepsy and outcomes' and 'newly diagnosed epilepsy and prognosis'. Search results were reviewed manually to identify relevant publications. All studies with a minimum of 100 patients, who were followed up for at least 2 years, were included in this review (see Tables 1 and 2) .
Results from studies of prognosis of epilepsy are often conflicting. Some of the variability can be explained on the basis of differences in populations and methodologies. As the underlying cause of epilepsy can be widely varied, data from studies that 'lump' together all epilepsy types will be skewed in favour of those most frequent in the population. Studying well-defined epilepsy (electroclinical) syndromes separately can provide better prognostic information, but accurate classification is not always achievable even in patients attending specialist services. Studies based in specialist clinics can be expected to have better characterised patient groups, but may be biased towards the more severe epilepsies. Retrospective studies, especially those from specialist clinics, may not include patients with milder forms of epilepsy.
Studies that identify all persons with new onset epilepsy in a defined population over a fixed period of time and follow them up prospectively will have the least recruitment bias. However, identifying all cases can be challenging and the diagnosis may be Seizure 22 (2013) [333] [334] [335] [336] [337] [338] [339] [340] [341] [342] [343] [344] Longitudinal studies of newly diagnosed epilepsy in children and adults have identified prognostic factors that allow early identification of patients whose seizures are likely to remain uncontrolled with antiepileptic medication. Results from outcome studies may be subject to bias, depending on the setting (community versus clinic), design (retrospective versus prospective) and characteristics of the patient cohort studied (age, types of epilepsy, specific comorbidities). Nevertheless, factors such as early response to medication, underlying aetiology, and number of seizures prior to initiation of treatment have consistently been found to be predictive of seizure outcomes. Other variables such as age, electroencephalographic findings and the presence or absence of psychiatric co-morbidities have been correlated with outcomes in some analyses. This review has examined studies of seizure outcomes in adults and children with newly diagnosed epilepsy identifying the risk factors that are associated with subsequent refractory epilepsy. Table 1 List of studies of outcomes in adult epilepsy. Studies from the same population have been grouped together. Studies marked with * (asterix) also inlcuded children.
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Recruitment period less secure in the non-specialist setting. 10 Such studies are also resource intensive and very few have been conducted. Alternatively those run by epilepsy specialists are open to the criticism that they are unlikely to be population-based. Studies of prognosis in newly diagnosed epilepsy examine the likelihood of seizure remission with AED therapy, or the likelihood of developing refractory epilepsy, usually defined in terms of the number of AEDs unsuccessfully tried. 11, 12 While failure to achieve remission with AED therapy does not always equate to refractory epilepsy, we feel that both outcome measures represented poor outcomes and have included studies of remission and of refractory epilepsy in this analysis. Seizure types, aetiology, age of onset, duration of epilepsy and number of seizures before starting AED treatment, history of febrile convulsions, presence of neurological, intellectual or psychiatric co-morbidity family history of epilepsy, electro-encephalographic findings and early response to AED treatment are some of the variables that have been examined by a number of authors. Their conclusions regarding each variable are summarised below.
Seizure types
Some studies have suggested a significant effect of seizure types on prognosis. In the population based study in Rochester, Minnesota, Annegers and colleagues found that patients with generalised tonic-clonic and absence seizures had 80 and 85% probability respectively of achieving remission, compared to only 65% for patients with complex partial seizures. 13 Analysis of data from two Veterans Affairs randomised control studies of AED treatment also showed that patients with complex partial seizures fared worst, with remission rates of 23 and 26% in the two studies compared to 55 and 48% for patients with generalised tonic-clonic seizures. 14 These low numbers can be, in part, explained by the inclusion of patients who had already failed their first treatment schedule. Smaller clinic-based studies, however, have also supported this finding. 15, 16 Patients experiencing multiple seizure types also appear to have worse outcomes in adults [17] [18] [19] and children. [20] [21] [22] However, another large community based study, the UK National General Practice Survey of Epilepsy (NGPSE), found only a modest effect of seizure type on prognosis. [23] [24] [25] Recent evidence implicates seizure clusters as being associated with poorer prognosis. 26 Analysis of these data overall, however, suggests that the effect of seizure types is less important than other factors including early response to treatment in determining eventual outcome.
Aetiology
Epilepsies relating to structural brain abnormalities are less likely to enter remission compared that occurring in patients with structurally normal brains. This is manifest as a lower remission rate for symptomatic epilepsies (both partial and generalised) compared to idiopathic epilepsy syndromes in children. 16, [27] [28] [29] [30] [31] The nature and location of the underlying structural abnormality can also affect the likelihood of response to treatment. Semah and colleagues found that in 2200 treated patients referred to a specialist epilepsy service in France, those with temporal lobe epilepsy were over represented compared to other types of localisation related epilepsy. 32 Analysis of 550 patients with localisation related epilepsy in Glasgow also reported worse remission rates in patient with hippocampal sclerosis than in focal epilepsies due to other causes. 33 However, many patients included in these analyses did not have newly diagnosed epilepsy, and so could be expected to have a substantially worse prognosis than found in similar studies in newly diagnosed populations. 34 Many patients with substrates for epilepsy often regarded as invariably being associated with drug resistance, such as hippocampal sclerosis, can have a good outcome and so may never be reviewed at a specialist service. 35, 36 The identification of well defined electro-clinical syndromes can allow more accurate assessment of prognosis. This is more pertinent to paediatric cases, where epilepsy syndromes are generally better defined. A detailed analysis of all published predictive factors in each epilepsy syndrome is beyond the scope of this article, only a few prominent examples will be touched upon.
In their meta-analysis of studies on childhood absence epilepsy, Bouma and colleagues found that significant heterogeneity existed between various cohorts in inclusion criteria and definition of remission. 37 As a result the reported remission rates ranged from 21% to 89%. Development of tonic-clonic seizures was associated with a reduced chance of remission (35%), compared to absence seizures only (78%), however, prognosis could not be predicted early on. Other studies have identified myoclonic jerks, eyelid or perioral myoclonia and presence of atypical EEG patterns as predictive of a poor prognosis in childhood absence epilepsy and subsequent evolution into juvenile myoclonic epilepsy (JME). 38, 39 Analysis of JME cohorts suggest that endophenotypes are important in determining prognosis, with good control of seizures with AED treatment but high rate of recurrence on withdrawal of medication.
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Age at onset
Some studies in children suggest that onset of epilepsy before the age of 12 months is a poor prognostic factor. 28, 30, 42 Berg and colleagues found that prognosis improved with increasing age, and that this effect was not restricted to the first year of life. 43 However, studies that included patients of all ages did not demonstrate a consistent effect of age at onset on prognosis. 13, 25 Multivariate analyses of prognostic factors in children 44 and in adults 15, 45 have found no independent correlation of age at onset with prognosis. It is likely that any differences are a reflection of the epilepsy syndromes that are prevalent among the various age groups. Mixed cohorts of various epilepsy syndromes cannot reflect the effect of individual syndromes on prognosis. In developed countries, the highest incidence of epilepsy is in older patients. 46 These present with epilepsy as a consequence of a variety of acquired brain disorders, including cerebrovascular disease and neurodegeneration. Analysis of the Glasgow cohort of newly diagnosed epilepsy suggested that outcomes were generally better in patients aged over 65 years at the onset of epilepsy. 47 Possible explanations include lack the neuronal plasticity needed for the development of pharmacoresistance and reduced likelihood of genetic factors adversely affecting prognosis.
Duration of epilepsy and number of pre-treatment seizures
Many studies have examined the impact of the number of seizures and the time from onset of epilepsy to starting AED treatment on prognosis. An important question for physicians is whether treating patients early, thereby minimising the number of subsequent seizures, will lead to improved outcomes. This is intricately linked to the question of whether drug resistance develops as a result of repeated seizures. The concept that ''seizures beget seizures'' was introduced by Gowers in the 19th century 48 and reinforced by the writings of Rodin in the 1960s. 49 A long history and high numbers of pre-treatment seizures were thought to correlate with a poor outcome. This view was supported by Reynolds and colleagues in the early 1980s and early treatment of seizures was considered key to preventing the emergence of drug-resistant epilepsy.
50 Table 2 List of studies of outcomes in paediatric epilepsy. Studies from the same population have been grouped together. Repeated seizures have been shown to produce neuronal loss and mossy fibre sprouting in the hippocampus, which in turn can reinforce their production forming excitatory recurrent circuits. 51 55, 56 Prevention of repeated seizures in this setting by effective drug treatment could theoretically prevent neuronal apoptosis and synaptic reorganisation, which may be responsible for further seizures and thereby the emergence of drug resistance. On the other hand, studies in patients who have suffered seizures for several years, sustaining 100 or more generalised seizures before coming to medical attention have shown that a similar proportion go into remission as patients treated early after only a few seizures. 57 Moreover, treatment with AEDs after the first unprovoked seizure has been shown not to affect the long-term outcome, in spite of preventing seizures in the short term. [58] [59] [60] [61] Several groups have shown a relationship of high initial seizure frequency with poor outcome. 18, 27, 49, [62] [63] [64] [65] [66] However, detailed analyses of data from observational studies have suggested that this is true only for patients suffering complex partial seizures. 67 This would imply that the epileptogenic process responsible for the high frequency of complex partial seizures is inherently pharmacoresistant, and supports the view that the prognosis of each epilepsy syndrome may be a characteristic of that specific disorder. 68 
Concomitant morbidity
In their landmark population based study of patients with epilepsy in Rochester Minnesota, Annegers and colleagues found that patients who had epilepsy as a result of presumed perinatal cerebral insult, manifesting as physical and intellectual disability had only 46% probability of achieving seizure control, compared to 74% for patients with idiopathic epilepsy and those with epilepsy due to postnatally acquired lesions. 13 Early clinic based studies also supported this notion in adults. 15 Subsequent studies, especially in children, have demonstrated that the presence of neurological deficit, especially associated with intellectual impairment, is indicative of a poorer prognosis. 20, 29, 44, 69 However, studies that include all age groups and predominantly adult patients have not supported such an association. The NGPSE and Glasgow cohorts showed no significant effect of neurological or intellectual deficits on prognosis 25, 66 Psychiatric problems are more frequent in patients with epilepsy. There is evidence to support a close relationship in the pathogenesis of epilepsy and depression. 70 Association of psychiatric co-morbidity with refractory epilepsy has previously been reported in adult patients. 15 In the Glasgow cohort of 780 patients with newly diagnosed epilepsy, Hitiris and colleagues noted that the presence of prior or current psychiatric comorbidity was significantly associated with failure to achieve remission. 66 Similar observations have been made following temporal lobectomy in patients with refractory epilepsy reporting a psychiatric history. 71, 72 More recently, Petrovski and colleagues demonstrated that the presence of neuropsychological symptomatology was associated with a worse response to treatment in patients with newly diagnosed epilepsy. 73 Other neuropsychological factors may also be important in determining prognosis. One small clinic based study found that patients with newly diagnosed epilepsy had verbal memory impairment 74 and that impaired memory performance at the outset was predictive of poor outcome. 16 It is possible, therefore that the presence of a psychiatric co-morbidity early in the course of the epilepsy points to a greater underlying cerebral dysfunction and is, therefore, predictive of a poorer outcome.
Family history of epilepsy
Studies in children 31 and adults 15, 66 have reported an association between family history of epilepsy and poorer prognosis. In generalised syndromes, this could be related to the underlying genetic mechanisms underpinning the epilepsy, which might also be responsible for determining drug response. 75 The role of genetic factors in focal epilepsies is less clear. Genetically determined malformations of cortical development may play a role 76 as may pharmacogenetic traits that run in families. 77 
Febrile seizures
Febrile seizures have an almost uniformly benign prognosis. However, approximately 3% of affected infants will develop epilepsy in later life. 78 Complex febrile seizures, i.e. those that are prolonged, focal or recur within the same day, those occurring in children with pre-existing neurological deficit, and those with a family history of epilepsy in a first degree relative, all confer a higher risk of developing epilepsy. There is, of course, a well known association between febrile seizures in infancy and the development of hippocampal sclerosis in later life. 78 Hitiris and colleagues 66 found that the febrile convulsions in infancy predicated a poorer outcome to treatment in newly diagnosed epilepsy as did Geerts and co-workers from the Netherlands. 22 
Electroencephalographic findings
Some studies, mainly in children, have found a correlation of background slowing and focal spike and wave activity with a poor outcome. 16, 28, 44 An electroencephalogram (EEG) performed soon after a seizure is more likely to detect such abnormalities, and is likely to have greater prognostic value. 79 Studies in adults have not found EEG to be independently predictive of outcome after adjusting for other factors. 15, 45 Thus, in adults, the prognostic value of routine interictal EEG examination has not been established.
Response to first drug
Several studies have found the response to the first AED to be the strongest predictor of long-term outlook in adults and children. 27, 64, [80] [81] [82] Patients whose seizures continue despite adequate doses of an appropriate AED have a lower chance of subsequent seizure remission, compared to those who are unable to do tolerate the initial AED, and are tried on an alternative agent. Kwan and Brodie reported that only 11% of patient who failed initial monotherapy due to lack of efficacy subsequently became seizure free, compared to 41% of those who failed due to intolerable adverse effects and 55% of those who experienced an idiosyncratic adverse effects. 80 If the first AED is unsuccessful, subsequent AED regimes have a declining likelihood of success. In an analysis of 780 patients diagnosed and treated for epilepsy in Scotland, the authors found that the response rate to the first, second and third AED was 50.4, 10.7 and 2.7%, respectively. 65 More recently responses have been demonstrated in a few patients up to the seventh regimen. 12, 82 The recently published International League against Epilepsy definition of drug-resistant epilepsy recommends that failure to gain seizure control for at least one year with the first 2 tolerated, appropriately chosen and used AED schedules (whether as monotherapy or in combination) should prompt referral for specialist review for confirmation of the diagnosis for seizure and/or syndrome classification and, if appropriate, for consideration of epilepsy surgery. 83 Some authors have suggested that this view might be unduly pessimistic and that further drug trials may still result in worthwhile improvements in seizure control for a proportion of patients. Callaghan and colleagues studied 246 patients who met the above definition of drug resistant epilepsy prospectively for 3 years, and reported a 14% 6-month remission rate (approximately 5% per year) with further drug therapy alone. 84 Luciano and Shorvon found that in a population of patients with refractory epilepsy, addition of a new AED resulted in seizure freedom in 16%. 85 Many of these patients however, will subsequently relapse. 11, 12, 86, 87 Good early response to AED treatment is not always sustained in the long term. Analysis of the Glasgow cohort found that 10.4% of patients entering remission had relapse of seizures, and 5% went on to develop drug resistant epilepsy. 65 Other hospital based series have reported the phenomenon of seizure relapse following an initial period of good response to AEDs and eventual development of drug resistant epilepsy. Following up a clinic population of 256 patients who had been seizure free for a minimum of 12 months, Schiller reported that 40% of patients had suffered seizure relapse by 5 years and 23% met the criteria for drug resistant epilepsy.
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The number of AEDs failed due to lack of efficacy and duration of epilepsy for more than 5 years before entering remission were identified as risk factors for relapse and subsequent development of refractory epilepsy. While most patients who respond to AED treatment will do so early, failure to do so does not indicate a uniformly poor prognosis. In the Glasgow series, of 780 newly diagnosed epilepsy patients, 245 (31.4%) became seizure free immediately after starting AEDs, achieving 12 months seizure freedom by one year of treatment, a further 217 patients also achieved the same outcome over the rest of the follow up. 65 A retrospective survey of 352 newly diagnosed patients from 2 epilepsy clinics in Italy reported that 56.2% entered 2 year remission immediately on starting treatment, but a further proportion achieved remission with each successive year of follow up, rising to a cumulative 2 year remission rate of 79% by 10 years of follow up. 88 In a long term prospective study of childhood onset epilepsy, Sillanpaa and Schmidt reported that patients who experienced ongoing weekly seizures during the first year on AED treatment were less likely to enter remission. 89 However, 50% of patients entered remission late, with a mean delay of 9 years from starting treatment. 90 The most recent analyses from the 1098 patients with newly diagnosed epilepsy included in the Glasgow database divided the patient outcomes into 4 distinct groups with 37.2% demonstrating longterm seizure freedom within 6 months of initiating treatment, 22.4% having a delayed response but an excellent outcome, 15.7% with a relapsing-remitting pattern and the final 24.8% being refractory de novo. 12 
Genetics of drug resistance
Pharmacogenetics is the study of genetic influences on the pharmacokinetics and pharmacodynamics of medications. This field has expanded enormously in parallel to the strides made in genetics technology. 91 A large number of genetic markers have been studied in patients with epilepsy to identify predictors of efficacy and adverse effects. 92 Single nucleotide polymorphisms represent the most frequently studied genetic marker to date, but genome wide association studies are underway. 77 Many studies have focussed on genes encoding the multidrug resistance protein MDR1 (ABCB1). This, and other similar proteins are thought to play a role in drug resistant epilepsy by extruding AEDs from the seizure focus. C3435T polymorphism in the ABCB1 gene has been found associated with refractory epilepsy in some studies, but a similar number failed to replicate this association. 93 It seems unlikely that a complex outcome such as responsiveness to AED treatment can be fully explained by variability of a single genetic factor. It is more likely that responsiveness to AED treatment depends on a complex interplay of genetic and environmental influences. 94 
Conclusions
Approximately one in three of patients diagnosed with epilepsy will fail to achieve lasting remission of seizures with AEDs treatment despite the global introduction of more than 12 new AEDs over the past 20 years. 68 These patients continue to suffer the physical, psychological and social consequences of intractable seizures and adverse effects from an escalating drug burden. They also place a strain on health care resources the world over. 95 While there is a clear need for new AEDs with novel mechanisms of action, there is also a need to target available treatments, especially epilepsy surgery, more effectively. Early identification and prediction of patients likely to be unresponsive to initial drug therapy will allow earlier specialist intervention. Advances in cerebral imaging and molecular biological techniques have allowed a greater insight into the mechanisms underlying seizure generation and propagation. However, this knowledge is far from complete. The basic mechanisms of drug resistance in epilepsy also remain largely unclear. Epidemiological data over the years have identified several factors that correlate with a poor prognosis in children and adults, although some of this data is conflicting. More long-term studies are required to assess the prognosis of each epilepsy syndrome. Pharmacogenomic studies employing more sophisticated genotyping and bioinformatics technologies promise greater predictability of response to individual AEDs. Other possibilities include the identification of biomarkers for drug-resistance, such as transcranial magnetic stimulation. 96 Studies to date show that the early response to treatment is a powerful predictor of the longterm outlook of newly diagnosed epilepsy. Patients who do not achieve complete seizure control with the first two appropriate regimens of AEDs in the first one to two years after starting treatment, have a relatively small chance of achieving seizure freedom with further pharmacotherapy and may be considered to have drug-resistant epilepsy. 12 There is, therefore, an urgent unmet need for new symptomatic treatments with improved efficacy/tolerability profiles and, arguably more importantly, disease-modifying approaches that will prevent or ameliorate the processes underpinning epileptogensis. 97 
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